Skip to main content
Top
Published in: Clinical Pharmacokinetics 1/2001

01-12-2001 | Original Research Article

Effects of Dairy Products on the Oral Bioavailability of Moxifloxacin, a Novel 8-Methoxyfluoroquinolone, in Healthy Volunteers

Authors: Dr Heino Stass, Dagmar Kubitza

Published in: Clinical Pharmacokinetics | Special Issue 1/2001

Login to get access

Abstract

Objective

To investigate the effect of concomitant administration of dairy products on the pharmacokinetics and tolerability of moxifloxacin.

Design

This was a single-centre, randomised, controlled, nonblinded, 2-way crossover study in healthy volunteers.

Participants

12 healthy men (aged 25 to 46 years) were enrolled in the study.

Methods

The plasma and urinary pharmacokinetics of moxifloxacin were investigated after single doses of moxifloxacin 400mg administered orally either under fasting conditions or immediately after 250g of yoghurt that was to be consumed within 15 minutes. There was a 1-week interval between the study periods.

Results

Administration of moxifloxacin after yoghurt had no effect on the extent of absorption, as estimated by the area under the plasma concentration-time curve from zero to infinity [AUC∞; geometric means 31.8 versus 33.9 mg/L · h after test and reference, respectively; estimated true treatment ratio 94%, 90% confidence interval (CI) 90 to 98%]. The rate of absorption was slightly decreased, with a slight reduction in maximum plasma concentration (Cmax; geometric means 2.44 versus 2.87 mg/L; estimated true treatment ratio 85%, 90% CI 74 to 98%) and a prolonged time to reach Cmax (tmax; median 2.75 versus 0.88 hours). The treatments were well tolerated in these healthy individuals.

Conclusions

The effects of yoghurt on the pharmacokinetics of moxifloxacin are considered not clinically relevant. Hence, no special recommendations for administration are required when moxifloxacin is given together with dairy products.
Literature
1.
go back to reference Dalhoff A, Petersen U, Endermann R. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 1996; 42: 410–25CrossRef Dalhoff A, Petersen U, Endermann R. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 1996; 42: 410–25CrossRef
2.
go back to reference Blondeau JM, Felmingham D. In vitro and in vivo activity of moxifloxacin against community respiratory tract pathogens. Clin Drug Invest 1999; 18: 57–78CrossRef Blondeau JM, Felmingham D. In vitro and in vivo activity of moxifloxacin against community respiratory tract pathogens. Clin Drug Invest 1999; 18: 57–78CrossRef
3.
go back to reference Jacobs E, Dalhoff A, Brunner H. Efficacy of BAY 12-8039 in Mycoplasma pneumoniae infected guinea pigs [abstract no. F17]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15–18; New Orleans, Louisiana: 102 Jacobs E, Dalhoff A, Brunner H. Efficacy of BAY 12-8039 in Mycoplasma pneumoniae infected guinea pigs [abstract no. F17]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15–18; New Orleans, Louisiana: 102
4.
go back to reference Neuvonen PJ, Kivisto KT, Lehto P. Interference of dairy products with the absorption of Ciprofloxacin. Clin Pharmacol Ther 1991; 50(5 Pt 1): 498–502CrossRef Neuvonen PJ, Kivisto KT, Lehto P. Interference of dairy products with the absorption of Ciprofloxacin. Clin Pharmacol Ther 1991; 50(5 Pt 1): 498–502CrossRef
5.
go back to reference Neuvonen PJ, Kivisto KT. Milk and yoghurt do not impair the absorption of Ofloxacin. Br J Clin Pharmacol 1992; 33: 346–8CrossRef Neuvonen PJ, Kivisto KT. Milk and yoghurt do not impair the absorption of Ofloxacin. Br J Clin Pharmacol 1992; 33: 346–8CrossRef
6.
go back to reference Kivisto KT, Ojala-Karlsson P, Neuvonen PJ. Inhibition of norfloxacin absorption by dairy products. Antimicrob Agents Chemother 1992; 36(2): 489–91CrossRef Kivisto KT, Ojala-Karlsson P, Neuvonen PJ. Inhibition of norfloxacin absorption by dairy products. Antimicrob Agents Chemother 1992; 36(2): 489–91CrossRef
7.
go back to reference Stass H, Dalhoff A. Determination of BAY 12-8039, a new 8-methoxyquinolone, in human body fluids by high-performance liquid chromatography with fluorescence detection using on-column focusing. J Chromatogr B Biomed Sci Appl 1997; 702: 163–74CrossRef Stass H, Dalhoff A. Determination of BAY 12-8039, a new 8-methoxyquinolone, in human body fluids by high-performance liquid chromatography with fluorescence detection using on-column focusing. J Chromatogr B Biomed Sci Appl 1997; 702: 163–74CrossRef
8.
go back to reference Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker Inc., 1982 Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker Inc., 1982
9.
go back to reference Lomaestro BM, Bailie GR. Absorption interactions with fluoroquinolones. 1995 update. Drug Saf 1995; 12: 314–33CrossRef Lomaestro BM, Bailie GR. Absorption interactions with fluoroquinolones. 1995 update. Drug Saf 1995; 12: 314–33CrossRef
10.
go back to reference Deppermann KM, Lode H. Fluoroquinolones: interaction profile during enteral absorption. Drugs 1993; 45 Suppl. 3: 65–72CrossRef Deppermann KM, Lode H. Fluoroquinolones: interaction profile during enteral absorption. Drugs 1993; 45 Suppl. 3: 65–72CrossRef
11.
go back to reference Lomaestro BM, Bailie GR. Quinolone-cation interactions: a review. DICP 1991; 25: 1249–58CrossRef Lomaestro BM, Bailie GR. Quinolone-cation interactions: a review. DICP 1991; 25: 1249–58CrossRef
12.
go back to reference Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999; 43 Suppl. B: 83–90CrossRef Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999; 43 Suppl. B: 83–90CrossRef
13.
go back to reference Ballow C, Lettieri J, Agarwal V, et al. Absolute bioavailability of moxifloxacin. Clin Ther 1999; 21: 513–22CrossRef Ballow C, Lettieri J, Agarwal V, et al. Absolute bioavailability of moxifloxacin. Clin Ther 1999; 21: 513–22CrossRef
14.
go back to reference Stass H, Kubitza D, Unger S. The effect of food on the oral bioavailability of moxifloxacin in healthy male volunteers. Moxifloxacin in Practice 2000; 3: 15–23 Stass H, Kubitza D, Unger S. The effect of food on the oral bioavailability of moxifloxacin in healthy male volunteers. Moxifloxacin in Practice 2000; 3: 15–23
15.
go back to reference Fleisher D, Li C, Zhou Y, et al. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin Pharmacokinet 1999; 36: 233–54CrossRef Fleisher D, Li C, Zhou Y, et al. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin Pharmacokinet 1999; 36: 233–54CrossRef
16.
go back to reference Tschanz C, Stargel WW, Thomas JA. Interactions between drugs and nutrients. Adv Pharmacol 1996; 35: 1–26CrossRef Tschanz C, Stargel WW, Thomas JA. Interactions between drugs and nutrients. Adv Pharmacol 1996; 35: 1–26CrossRef
17.
go back to reference Müller B A, Brierton DG, Abel SR, et al. Effect of enterai feeding with ENSURE on oral bioavailabilities of Ofloxacin and Ciprofloxacin. Antimicrob Agents Chemother 1994; 38(9): 2101–5CrossRef Müller B A, Brierton DG, Abel SR, et al. Effect of enterai feeding with ENSURE on oral bioavailabilities of Ofloxacin and Ciprofloxacin. Antimicrob Agents Chemother 1994; 38(9): 2101–5CrossRef
18.
go back to reference Food-effect bioavailability and bioequivalence studies. Draft Guidance for Industry. Bethesda (MD): US Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research, BPX Oct 1997 Food-effect bioavailability and bioequivalence studies. Draft Guidance for Industry. Bethesda (MD): US Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research, BPX Oct 1997
19.
go back to reference Stass H, Wandel C, Delesen H, et al. The effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers [abstract no. 132]. J Antimicrob Chemother 1999; 44 Suppl. A: 416 Stass H, Wandel C, Delesen H, et al. The effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers [abstract no. 132]. J Antimicrob Chemother 1999; 44 Suppl. A: 416
20.
go back to reference Sullivan JT, Kubitza D, Schühly U, et al. Safety of the new quinolone BAY 12-8039 in 130 healthy volunteers [abstract no. 3355]. 20th International Congress on Chemotherapy; 1997 29 Jun–3 Jul; Sydney, Australia: 108 Sullivan JT, Kubitza D, Schühly U, et al. Safety of the new quinolone BAY 12-8039 in 130 healthy volunteers [abstract no. 3355]. 20th International Congress on Chemotherapy; 1997 29 Jun–3 Jul; Sydney, Australia: 108
Metadata
Title
Effects of Dairy Products on the Oral Bioavailability of Moxifloxacin, a Novel 8-Methoxyfluoroquinolone, in Healthy Volunteers
Authors
Dr Heino Stass
Dagmar Kubitza
Publication date
01-12-2001
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue Special Issue 1/2001
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.2165/00003088-200140001-00005

Other articles of this Special Issue 1/2001

Clinical Pharmacokinetics 1/2001 Go to the issue